好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Primary Brain and Central Nervous System Tumor Treatment and Survival in the United States, 2004-2014
Neuro-oncology
S30 - Brain Cancer: From Epidemiology to Quality of Life (4:03 PM-4:14 PM)
004
Primary brain tumor treatment and survival information is limited in cancer datasets. Survival evaluations are warranted due to the molecular heterogeneity of these diseases.
We provide an updated clinical investigation on the management and survival estimates for brain and central nervous system (CNS) tumors in the United States.

We analyzed the National Cancer Database (NCDB) from 2004-2014 for all patients with diagnosis of primary brain and CNS tumors. NCDB collects long-term survival data for over 70% of all newly diagnosed cancers.

464,852 patient tumor records were identified. The most common histology was meningioma (43.4%), followed by glioblastoma (21.9%), and nerve sheath tumors (10.6%). Median age was 60 years, with a female (57.9%), white (85.2%), and non-Hispanic (87.5%) predominance. WHO grade I accounted for 43.7% of the patients, grade II for 6.5%, grade III 4.5%, grade IV for 23.8%, WHO grade unknown for 7.9%, and the remaining 13.7% included histology groups where WHO grade is not used. Overall, 56% underwent surgical procedures, 30.4% received radiation, and 20.5% received chemotherapy. Radiation, plus chemotherapy and surgery was the most common treatment modality in high-grade tumors (47.6%), while surgery only (42.7%) or watchful waiting (41.4%) was preferred in low-grade tumors. Median survival was 9 years for all primary brain tumors, but varied significantly by histology group. Median survival was 13 years for grade I tumors, 12 years in grade II, 3 years in grade III, and 10 months in grade IV. Older age, male gender, white race, higher number of comorbidities, and lower socioeconomic status were identified as risk factors for mortality.

We provide the largest investigation of primary brain tumors with similar outcomes to those reported for population-based datasets. Our analysis provides benchmark survival estimates and treatment outcomes throughout the United States with significant opportunity for improvement. 

Authors/Disclosures
Catherine Garcia, MD (MD Anderson Cancer Center)
PRESENTER
Dr. Garcia has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file